Establishments primarily engaged in manufacturing in vitro and in vivo diagnostic substances, whether or not packaged for retail sale. These materials are chemical, biological, or radioactive substances used in diagnosing or monitoring the state of human or veterinary health by identifying and measuring normal or abnormal constituents of body fluids or tissues.
The NAICS 2835, In Vitro and In Vivo Diagnostic Substances industry has witnessed pivotal qualitative trends that emphasize technological advancement and personalized medicine. There is an ongoing surge in the integration of artificial intelligence and machine learning in diagnostic processes, enhancing accuracy and reducing time-to-results. Furthermore, the development of point-of-care testing (POCT) devices is streamlining diagnostics to be more accessible, allowing for faster and more efficient healthcare delivery.
The COVID-19 pandemic has accelerated the demand for both in vitro and in vivo diagnostic solutions, promoting innovations in remote and at-home testing kits. This shift is expected to persist, with consumers seeking convenience and safety in health diagnostics. Additionally, the industry is seeing a stronger emphasis on precision medicine, encouraging the development of diagnostic tools tailored to individual genetic profiles.
In the near future, forecasts predict continued growth in the adoption of digital health technologies and wearables that monitor health conditions in real-time. Collaborations between biotech firms and tech companies are likely to proliferate, aiming to deliver more integrated and comprehensive diagnostic solutions. As regulatory frameworks adapt to these innovations, the market is projected to expand further, driven by heightened awareness and demand for proactive health management.
Angiourographic diagnostic agents
Barium diagnostic agents
Blood derivative diagnostic reagents
Clinical chemistry reagents (including toxicology)
Clinical chemistry standards and controls (including toxicology)
Coagulation diagnostic reagents
Cold kits for labeling with technetium
Contrast media diagnostic products (e.g., iodine and barium)
Cytology and histology diagnostic products
Diagnostic agents, biological
Electrolyte diagnostic reagents
Enzyme and isoenzyme diagnostic reagents
Hematology diagnostic reagents
In vitro diagnostics
In vivo diagnostics
In vivo radioactive reagents
Iodinated diagnostic agents
Metabolite diagnostic reagents
Microbiology, virology, and serology diagnostic products
Pregnancy test kits
Radioactive diagnostic substances
Technetium products
Viral test diagnostic reagents
A review and comparison of financial performance of privately-help companies in specified SIC/NAICS industry segment, using industry standard benchmarks.
Answers come easily with iCFO. Review ROI, sales per employee, profit margins of the top 10%, top 25% and more, to identify areas of concern and opportunity. Examine what if scenarios and P&L impact of reducing costs or adding revenue.
It takes only five minutes to enter your data and produce a concise profile of your company’s fiscal state, including critical business ratios focusing on liquidity, profitability, asset efficiency, and growth.